Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2025 Earnings Call Transcript
Rebecca: Good afternoon, everyone. And welcome to Gilead Sciences, Inc.'s First Quarter 2025 Earnings Conference Call. My name is Rebecca, and I'll be today's host.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 666,108 | $74,637,359 | -2% | 1.93% |
| 2. | Impax Asset Management Ian Simm | 284,006 | $31,822,872 | -26% | 0.19% |
| 3. | Leucadia National Ian Cumming And Joseph Steinberg | 263,899 | $29,569,883 | +21% | 0.26% |
| 4. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 76,998 | $8,627,626 | 3.81% | |
| 5. | Royce & Associates Chuck Royce | 68,000 | $7,619,400 | -3% | 0.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | Director | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | Director | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | Director | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | Director | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | Director | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $106.40 | 2,500 | Officer | 168,174 | 2025-04-15 | Filing | |
| $110.53 | 2,500 | Officer | 170,674 | 2025-03-17 | Filing | |
| $118.50 | 13,013 | Officer | 169,061 | 2025-03-10 | Filing | |
| $117.30 | 4,916 | Officer | 182,074 | 2025-03-10 | Filing | |
| $104.09 | 2,500 | Officer | 169,061 | 2025-02-18 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 117,470,825 | $13,162,605,942 | 0.24% | |
| 2. | 116,104,572 | $13,009,517,311 | 0.27% | |
| 3. | 15,803,586 | $1,770,791,811 | 0.35% | |
| 4. | 8,015,530 | $898,140,137 | 0.17% | |
| 5. | 6,794,197 | $761,289,878 | 0.12% |
News See All
11 Cheap NASDAQ Stocks to Buy According to Hedge Funds
On April 10, Dan Ives, Head of Global Tech Research at Wedbush Securities, appeared on an interview at CNBC and expressed that the tech sector could be heading into a period of major volatility.
11 Most Undervalued Quality Stocks to Buy Now
On February 24, Kayne Anderson Rudnick chief market strategist Julie Biel joined 'The Exchange' on CNBC to discuss her thoughts on how good quality companies can ride out turbulence in the market.
Multiple Tailwinds Lifted Gilead Sciences (GILD) in Q1
ClearBridge Investments, an investment management company, released its “ClearBridge Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
7 Most Undervalued Biotech Stocks To Invest In
On February 21, Jared Holz, Mizuho Securities America's healthcare sector strategist, appeared on CNBC to discuss Trump's tariffs and their effects on the American pharma sector.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds
The NASDAQ Index closed more than 10% below its December high of 20,174 on March 6, 2025. This officially puts the index in a market correction – which has happened a dozen times since 2010.
11 Best Pharma Stocks to Buy According to Hedge Funds
The US pharmaceutical sector is experiencing a distinct trend never seen before with large American pharma companies continually looking for medicines in China.
Top 10 Stocks Wall Street is Discussing
Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the market rally that started during the peak of the pandemic driven by fiscal stimulus seems to have...
Renaissance Technologies Portfolio: Top 10 Stock Picks
The American quant hedge fund Renaissance Technologies is known for using statistical and mathematical tools to drive its investment programs.